CA2826513C - Compositions renferment un sel de propofol et une cyclodextrine - Google Patents
Compositions renferment un sel de propofol et une cyclodextrine Download PDFInfo
- Publication number
- CA2826513C CA2826513C CA2826513A CA2826513A CA2826513C CA 2826513 C CA2826513 C CA 2826513C CA 2826513 A CA2826513 A CA 2826513A CA 2826513 A CA2826513 A CA 2826513A CA 2826513 C CA2826513 C CA 2826513C
- Authority
- CA
- Canada
- Prior art keywords
- propofol
- formulation
- salt
- cyclodextrin
- dissolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical class CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960004134 propofol Drugs 0.000 claims abstract description 27
- 238000009472 formulation Methods 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- -1 2-hydroxypropyl- Chemical group 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 229940031576 hydroxypropylbetadex (0.58-0.68 ms) Drugs 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 206010047095 Vascular pain Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une formulation pharmaceutique contenant un complexe d'un sel de propofol et d'une cyclodextrine. L'invention permet de mettre en oeuvre du propofol dans une formulation qui peut être stockée et appliquée sans problème par voie-intra-veineuse.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2012/000391 WO2012104730A1 (fr) | 2011-02-04 | 2012-03-01 | Préparation pharmaceutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2826513A1 CA2826513A1 (fr) | 2012-08-09 |
| CA2826513C true CA2826513C (fr) | 2019-02-05 |
Family
ID=49221649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2826513A Expired - Fee Related CA2826513C (fr) | 2012-03-01 | 2012-03-01 | Compositions renferment un sel de propofol et une cyclodextrine |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101889121B1 (fr) |
| CA (1) | CA2826513C (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| KR20040091004A (ko) * | 2002-02-01 | 2004-10-27 | 쉬모다 바이오테크(피티와이) 리미티드 | 약제학적 조성물 |
-
2012
- 2012-03-01 KR KR1020137023297A patent/KR101889121B1/ko active IP Right Grant
- 2012-03-01 CA CA2826513A patent/CA2826513C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140120254A (ko) | 2014-10-13 |
| CA2826513A1 (fr) | 2012-08-09 |
| KR101889121B1 (ko) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9006215B2 (en) | Pharmaceutical preparation comprising propofol salt and cyclodextrin | |
| US11246851B2 (en) | Pharmaceutical compositions of furosemide and uses thereof | |
| EP2679227B1 (fr) | Nanoparticule contenant un dérivé de prostaglandine i2 | |
| CN107625967B (zh) | 一种特考韦瑞注射用药物组合物及其制备方法 | |
| CN103079559A (zh) | 包含胺碘酮及其盐的制剂及其制造和使用方法 | |
| WO2013003306A1 (fr) | Compositions pharmaceutiques pour administration parentérale | |
| US20080233196A1 (en) | Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles | |
| CN104507467B (zh) | 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂 | |
| AU2011304917B2 (en) | 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method therefor | |
| CN108697726A (zh) | 液态药物制剂 | |
| CA2826513C (fr) | Compositions renferment un sel de propofol et une cyclodextrine | |
| EP3173071B1 (fr) | Formulation de maropitant | |
| CN102451176A (zh) | 多西紫杉烷/类固醇复合物 | |
| CZ2005796A3 (cs) | Farmaceutická kompozice obsahující derivát taxanuse zlepsenou terapeutickou úcinností | |
| JP2010030906A (ja) | 難水溶性薬剤の薬液製剤、その薬液製剤製造方法および希釈薬液製剤製造方法 | |
| CN101590029B (zh) | 一种丙泊酚组合物 | |
| Apridamayanti et al. | Formulation vitamin C using niosomes system span 80 in gel for increase stability and penetration in vitro | |
| JP4475405B2 (ja) | 医薬組成物 | |
| WO2011104631A1 (fr) | Compositions de sn-38 | |
| CN106337077B (zh) | 化学限定高密度cho培养基的难溶脂肪酸母液及其制备方法 | |
| WO2008099084A1 (fr) | Composition pharmaceutique parentérale et son procede de preparation. | |
| CN102697720A (zh) | 盐酸伊立替康脂质纳米粒注射剂 | |
| JP2015522608A (ja) | 注射用抗生物質製剤およびその使用方法 | |
| KR20120034226A (ko) | 알킬포스포콜린의 액상 제약 형태 및 그의 제조 방법 | |
| JP2011020967A (ja) | ベンズイミダゾール系注射剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170119 |
|
| MKLA | Lapsed |
Effective date: 20210901 |
|
| MKLA | Lapsed |
Effective date: 20200302 |